SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant sell-off after providing cautious revenue guidance for the upcoming quarter, despite beating previous earnings estimates. This has led to widespread debate, with many viewing the stock as overvalued and lacking immediate growth catalysts, while others see the sharp dip as a compelling buying opportunity, emphasizing its strategic national importance and future foundry potential.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. (QCLS) is actively trending amid excitement over its strategic positioning in cutting-edge quantum-class computing and photonic technology, bolstered by the recent appointment of an OpenAI AI systems leader to its board. Community discussions highlight strong belief in the company's potential, with many anticipating significant upside due to its perceived undervaluation and growing calls for a short squeeze. Investors are closely monitoring price action, navigating persistent market manipulation concerns while noting the high short interest.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending after the US updated deep-sea mining regulations, enabling the company to file a consolidated application that significantly expands its exploration territory. The community is highly bullish, anticipating rapid permit approval and future production as a critical move for national security and reducing reliance on foreign mineral supply chains. Many expect substantial upside and a potential short squeeze, driven by perceived government backing and the urgency to secure essential resources for industries like EVs.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing extreme volatility and intense debate ahead of its upcoming earnings report, driven by an AI-fueled memory shortage narrative. Bulls are confidently buying dips, anticipating further upside, while bears vociferously warn of an unsustainable "bull trap" due to its parabolic rise and perceived overvaluation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is generating significant conversation among investors, many of whom are keenly awaiting updates on new AI/HPC data center contracts amid perceived silence from management. While some express frustration over market manipulation and the stock's lagging performance compared to peers, others remain bullish, citing its strong position in the growing AI infrastructure sector and anticipating a potential short squeeze. The debate centers on whether the company can capitalize on its strategic alliances and overcome current market skepticism.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is experiencing significant trading volume following news that its merger partner, Corvex, has secured a long-term NVIDIA H200 GPU deployment, aligning the company with the robust AI infrastructure sector. This catalyst, combined with an extremely low share float, has created highly polarized sentiment: many traders anticipate a massive short squeeze, while others caution that the move is unsustainable and risks further dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following promising Phase 2 data for its glioblastoma treatment, with conversations highlighting that median overall survival has not yet been reached, signaling exceptional patient outcomes for this challenging cancer. The community is widely discussing the positive implications of this data, along with high short interest, as potential drivers for significant upward momentum. Many express strong conviction in the company's innovative immunotherapy platform and future catalysts.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is seeing intense community discussion and significant price action, with many highlighting its Breakthrough Therapy Designation for Pemvidutide as a 'best in class' MASH and obesity drug with strong buyout potential. This surge is further fueled by discussions around the stock's undervaluation compared to peers and potential for a short squeeze, even as some skeptics label the rally a 'pump and dump' lacking new fundamental catalysts.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following unprecedented demand for its new oral Wegovy pill, with initial prescription numbers significantly surpassing market expectations and prompting analyst upgrades. The community is buzzing, actively debating whether current price action reflects market manipulation and geopolitical "noise" or if the company's strong oral GLP-1 market entry signals an imminent upward repricing, given the vast potential for needle-free obesity treatments.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing a volatile trading session driven by strong performance in select mega-cap tech stocks like Microsoft and Meta, while broader market indices and small caps show weakness. Community sentiment is sharply divided, with some actively buying dips amidst a falling dollar and rising consumer confidence, while others anticipate a significant market correction due to upcoming central bank decisions and geopolitical tensions, prompting discussions around holding positions over the weekend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BDTX  
So undervalued. Cannot understand what the street missed after the P2 presentation, other than basic scientific understanding. 🤦‍♂️ 
 
Well, good time to buy. 🦶🏿

Mr.Blockchain

Glen Schackier

StockTwits Web

Black Diamond Therapeutics Inc

  
So undervalued. Cannot understand what the street missed after the P2 presentation, other than basic scientific understanding. 🤦‍♂️ 
 
Well, good time to buy. 🦶🏿

SELLAS Life Sciences Group Inc

Candel Therapeutics Inc

NeuroSense Therapeutics Ltd

Stock_Squatch_Watcher

@Stock_Squatch_Watcher 
I think the market didn’t love the safety profile of the drug much.  But still definitely a positive outcome, so far.

StockTwits for iOS

 
I think the market didn’t love the safety profile of the drug much.  But still definitely a positive outcome, so far.

Wolfspeed Inc

Rigel Pharmaceuticals

Biohaven Pharmaceutical Holding Company Ltd

Citius Pharmaceuticals Inc

Verrica Pharmaceuticals Inc

Applied Therapeutics Inc

Amprius Technologies Inc

Bezad

@Bbboston  
More like the misunderstood it. Asian populations often respond differently (to drugs) vs. non-Asian populations. It is why Japan is usually the last country to get a drug approved in despite being approved in the US and Europe. They want/require specific trials to be conducted on their genetic population.  
 
Safety was still very good overall. ✌️🦶🏿

  
More like the misunderstood it. Asian populations often respond differently (to drugs) vs. non-Asian populations. It is why Japan is usually the last country to get a drug approved in despite being approved in the US and Europe. They want/require specific trials to be conducted on their genetic population.  
 
Safety was still very good overall. ✌️🦶🏿